RUFY1

Across TCGA pan-cancer cohorts, RUFY1 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated RUFY1 data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher RUFY1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RUFY1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

GBM, CCRCC, and PDAC are the cancer types where RUFY1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.754	0.875	.004	15	view →
CCRCC	OS	Tertile	All	0.784	1.000	<.001	13	view →
PDAC	OS	Tertile	IV	0.973	0.443	.024	12	view →
LUAD	OS	Tertile	All	0.863	0.402	.013	9	view →
LSCC	OS	Quartile	II,III,IV	0.709	1.000	.014	8	view →
UCEC	OS	Quartile	II,III,IV	0.421	1.000	.045	4	view →
HNSC	OS	Median	All	0.918	0.774	.014	4	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

RUFY1–GBM (OS)

Open the GBM breakdown →